ScoreWhy is Strides Pharma Science Ltd ?
1
Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.90 times
- Poor long term growth as Net Sales has grown by an annual rate of 9.20% over the last 5 years
- Low ability to service debt as the company has a high Debt to EBITDA ratio of 1.90 times
- The company has been able to generate a Return on Equity (avg) of 9.60% signifying low profitability per unit of shareholders funds
2
Healthy long term growth as Operating profit has grown by an annual rate 27.28%
3
The company has declared Positive results for the last 12 consecutive quarters
- OPERATING CF(Y) Highest at Rs 702.52 Cr
- ROCE(HY) Highest at 17.96%
- DEBT-EQUITY RATIO(HY) Lowest at 0.57 times
4
With ROCE of 15.5, it has a Very Attractive valuation with a 2.3 Enterprise value to Capital Employed
- The stock is trading at a discount compared to its peers' average historical valuations
- Over the past year, while the stock has generated a return of 23.58%, its profits have risen by 53.4% ; the PEG ratio of the company is 0.3
5
38.1% of Promoter Shares are Pledged
- In falling markets, high promoter pledged shares puts additional downward pressure on the stock prices
- The proportion of pledged holdings has increased by 10.83% over the last quarter
Real-Time Research ReportHow much should you hold?
- Overall Portfolio exposure to Strides Pharma should be less than 10%
- Overall Portfolio exposure to Pharmaceuticals & Biotechnology should be less than 30%
(If sector exposure > 30%, please use optimiser tool to see which are the best stocks to hold in Pharmaceuticals & Biotechnology)
When to exit? - We will constantly monitor the company and suggest at the appropriate time to exit from the stock
Is Strides Pharma for you?
High Risk, High Return
Absolute
Risk Adjusted
Volatility
Strides Pharma
23.78%
0.63
37.68%
Sensex
-1.97%
-0.15
13.56%
Quality
Management Risk
Growth
Capital StructureQuality key factors
Factor
Value
Sales Growth (5y)
9.20%
EBIT Growth (5y)
27.28%
EBIT to Interest (avg)
1.80
Debt to EBITDA (avg)
Negative Net Debt
Net Debt to Equity (avg)
0.50
Sales to Capital Employed (avg)
0.81
Tax Ratio
14.99%
Dividend Payout Ratio
8.29%
Pledged Shares
38.10%
Institutional Holding
43.81%
ROCE (avg)
7.49%
ROE (avg)
9.60%
ValuationValuation Key Factors 
Factor
Value
P/E Ratio
16
Industry P/E
37
Price to Book Value
2.96
EV to EBIT
14.79
EV to EBITDA
11.48
EV to Capital Employed
2.31
EV to Sales
2.15
PEG Ratio
0.30
Dividend Yield
0.50%
ROCE (Latest)
15.54%
ROE (Latest)
18.64%
Loading Valuation Snapshot...
TechnicalsTechnical key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Mildly Bearish
Mildly Bearish
Dow Theory
Mildly Bearish
Mildly Bearish
OBV
Mildly Bearish
Mildly Bearish
Technical Indicator Scale: Bearish, Mildly Bearish, Sideways, Mildly Bullish, Bullish Turned 
Financial Trend11What is working for the Company
OPERATING CF(Y)
Highest at Rs 702.52 Cr
ROCE(HY)
Highest at 17.96%
DEBT-EQUITY RATIO(HY)
Lowest at 0.57 times
DPR(Y)
Highest at 8.29%
PAT(9M)
Higher at Rs 441.96 Cr
-1What is not working for the Company
NO KEY NEGATIVE TRIGGERS
Loading Valuation Snapshot...
Here's what is working for Strides Pharma
Profit After Tax (PAT) - Nine Monthly
At Rs 441.96 cr has Grown at 46.84%
Year on Year (YoY)MOJO Watch
Near term PAT trend is very positive
PAT (Rs Cr)
Debt-Equity Ratio - Half Yearly
Lowest at 0.57 times and Fallen
each half year in the last five half yearly periodsMOJO Watch
The company has been reducing its borrowing as compared to equity capital
Debt-Equity Ratio
Operating Cash Flow - Annually
Highest at Rs 702.52 Cr
in the last three yearsMOJO Watch
The company has generated higher cash revenues from business operations
Operating Cash Flows (Rs Cr)
Profit After Tax (PAT) - Nine Monthly
Higher at Rs 441.96 Cr
than preceding 12 month period ended Jun 2026 of Rs 436.05 crMOJO Watch
In the nine month period the company has already crossed sales of the previous twelve months
PAT (Rs Cr)
Dividend Payout Ratio (DPR) - Annually
Highest at 8.29%
in the last five yearsMOJO Watch
Company is distributing higher proportion of profits generated as dividend
DPR (%)
InfinHub Market Technologies FZ-LLC, Building-2, Unit 112, Dubai Internet City, Dubai, United Arab Emirates
GET THE MARKETSMOJO APP
Company
Stocks
Portfolio
"Investment in securities markets are subject to market risk. Read all the related documents carefully before investing."
